Axicabtagene Ciloleucel — Drug Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

6 Recruiting

4 Completed trials

10 Sponsors

9 Countries

Phase III

Phase II

Phase IV

Phase III: 2 Phase II: 8 Phase I/II: 1 Phase IV: 2

Oversight events:

7 temporary halts 3 corrective measures across 3 trials

View oversight register →

Indications tested

Diffuse large B-cell lymphoma recurrent 2 Follicular lymphoma 1 B-cell unclassifiable lymphoma high grade 1 Diffuse large B-cell lymphoma stage I 1 Diffuse large B-cell lymphoma stage IV 1 Diffuse large B-cell lymphoma refractory 1 Diffuse large B-cell lymphoma stage III 1 High-grade B-cell lymphoma 1 Diffuse large B-cell lymphoma 1 Diffuse large B-cell lymphoma stage II 1

Sponsors using this IMP

Kite Pharma Inc. 4 Centre Hospitalier Universitaire De Saint Etienne 1 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 1 Fundacion Geltamo 1 Instytut Hematologii I Transfuzjologii 1 Lymphoma Academic Research Organisation 1 LYSARC 1 Universitaet Muenster 1 Universitair Medisch Centrum Groningen 1 Universitair Ziekenhuis Gent 1

All trials

13 total

A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/… Pending

2024-518275-64-00 Phase II 1 country Instytut Hematologii I Transfuzjologii
Double-T - Improving outcomes in high-risk 2nd line relapsed/refractory Large B-Cell Lymphoma patients eligible for CAR-T-cell therapy with … Pending

2025-523806-34-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy Pending

2025-524278-40-00 Phase IV 1 country Universitair Ziekenhuis Gent
Temporal characterization of Extracellular Vesicles during cellular therapy using CAR-T cells and during the occurrence of Immune effector C… Recruiting

2024-515328-35-00 Phase IV 1 country Centre Hospitalier Universitaire De Saint Etienne
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L… Recruiting

2022-501489-24-00 Phase III 7 countries Kite Pharma Inc.
LATE-R trial. A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients with Lat… Recruiting

2024-512835-53-00 Phase II 1 country Fundacion Geltamo
CARMOD - Golcadomide (BMS-986369) post-CAR T-cell in R/R Aggressive large B-cell lymphoma patients with high risk of relapse Recruiting

2023-506705-20-00 Phase II 1 country Lymphoma Academic Research Organisation
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells Recruiting

2023-507041-28-00 Phase II 7 countries Kite Pharma Inc.
HOVON 161: A phase II non-inferiority study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/… Recruiting

2024-511979-15-00 Phase II 1 country Universitair Medisch Centrum Groningen
A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L… Ended

2024-511594-30-00 Phase III 4 countries Kite Pharma Inc.
Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible … Ended

2024-513659-34-00 Phase I/II 1 country LYSARC
Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma Ended

2024-510972-19-00 Phase II 1 country Universitaet Muenster
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Ended

2023-505169-10-00 Phase II 1 country Kite Pharma Inc.

Showing 1–13 of 13 trials

← All drugs A–Z